Vildagliptin Market: Introduction

  • Vildagliptin is an antihyperglycemic medication that inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme selectively. It is used to treat type 2 diabetes mellitus, which is characterized by impaired GLP-1 production and insulinotropic effects. DPP-4 is inhibited. Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), both incretin hormones that stimulate insulin production and control blood glucose levels, are protected from breakdown by vildagliptin. GLP-1 and GIP levels are elevated, which leads to better glycemic control. Vildagliptin has been shown in clinical studies to have a minimal risk of hypoglycemia.

Read Report Overview - https://www.transparencymarketresearch.com/vildagliptin-market.html

  • The European Medicines Agency authorized oral vildagliptin for the treatment of type 2 diabetes mellitus in adults as monotherapy or in combination with metformin, a sulfonylurea, or a thiazolidinedione in patients with insufficient glycemic control after monotherapy in 2008. Galvus is the brand name for it. For individuals who do not achieve sufficient glycemic control with monotherapy, vildagliptin is now available as Eucreas, a fixed-dose formulation with metformin. In the U.S., vildagliptin is being investigated.

Key Drivers, Restraints, and Opportunities of Global Vildagliptin Market

  • The vildagliptin market is projected to be driven by an increase in disease prevalence and clinicians' efforts to postpone disease development and minimize the costly burden of diabetes complications through the use of combination treatments. As per WHO, the number of people with diabetes rose from 108 million in 1980 to 422 million in 2014, this number is estimated to rise to 700 million by 2045. 374 million people are at an increased risk of developing type 2 diabetes. Prevalence has been rising more rapidly in low- and middle-income countries than in high-income countries. In 2019, an estimated 1.5 million deaths were directly caused by diabetes. Another 2.2 million deaths were attributable to high blood glucose in 2015. According to the CDC, gestational diabetes can impact 4.6% to 9.2% of pregnancies during pregnancy and parenthood. In up to 10% of cases, the woman is diagnosed with type 2 diabetes shortly after giving birth. Within 10 to 20 years, the rest of these women had a 35% to 60% risk of acquiring type 2 diabetes. This is likely to boost the vildagliptin market. Older age; excess weight, particularly around the waist; family history; certain ethnicities; physical inactivity; and poor diet also increase the incidences of type 2 diabetes. All these factors lead to higher incidences of type 2 diabetes, which in turn fuels the vildagliptin market.

Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82933

North America to Capture Major Share of Global Vildagliptin Market

  • North America is expected to account for a major share of the global vildagliptin market, due to technological advancements, presence of major players, and a rise in prevalence of type 2 diabetes in the region. More than 34 million people in the U.S. have diabetes, and approximately 90% to 95% of them have type 2 diabetes. Type 2 diabetes most often develops in people over age 45; however, an increasing number of children, teens, and young adults are also developing it.
  • The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to an increase in prevalence of diabetes in the region. Presence of a large number of vildagliptin manufacturers in Asia is another factor that is projected to propel the market in the region.

Pre Book Vildagliptin Market Report- https://www.transparencymarketresearch.com/checkout.php?rep_id=82933&ltype=S

Key Players Operating in Global Vildagliptin Market

The global vildagliptin market is highly consolidated with the presence of key players. A large number of manufacturers hold a major share in their respective regions. Major players operating in the global vildagliptin market include:

  • Actis Generics Pvt Ltd.
  • Cipla
  • Eris Lifesciences
  • Farmavita
  • Medochemie
  • Metrochem API Pvt Ltd
  • Novartis

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/